• Tessa Therapeutics Establishes New Scientific Advisory Board

    Date: 22 May 2019 

    Tessa Therapeutics has established a new Scientific Advisory Board (SAB) with the appointment of a team of highly respected scientists, practicing clinicians and industry veterans. These appointments come at an important stage of the company’s growth, as Tessa looks to advance and broaden our cell therapy portfolio.

    The new SAB is chaired by Dr. Giulio Draetta, Senior Vice President and Chief Scientific Officer at The University of Texas MD Anderson Cancer Center, and comprises a line-up of distinguished members whose deep industry knowledge and extensive leadership experience will be hugely valuable in guiding and supporting Tessa for future growth.

    Learn more about our SAB members here.

  • Run for Hope 2019

    Date: 18 Feb 2019 |

    Over 100 Tessa colleagues, friends and family members participated in Run for Hope 2019 to support National Cancer Centre Singapore’s cancer research fund. We have been running for this cause since 2017 and we’re looking forward to raising more funds for cancer research next year!

  • Tessa hosted Chinese Premier, Li Keqiang, at our facility and discussed new ways to fight cancer

    Date: 13 Nov 2018 | More Details Here

    Tessa Therapeutics was honored to host Chinese Premier Li Keqiang on his first official visit to Singapore as Premier, where we discussed our commitment to clinical research and the need for international cooperation to develop new ways to fight cancer.


    2018年11月12日,中国李克强总理上任以来首次访问新加坡。11月13日,Tessa (特沙公司) 非常荣幸地接待了李总理的到访,详细介绍了公司的研发理念和进展。李总理鼓励新中两国企业开展研发合作,减轻癌症患者的病痛和家庭负担。更多详情请参考: http://paper.people.com.cn/rmrb/html/2018-11/14/nw.D110000renmrb_20181114_3-02.htm

     

     

    ***

    Tessa Therapeutics Media Contacts
    Brunswick Group
    Will Carnwath, Ben Fry
    TessaTherapeutics@brunswickgroup.com
    +65 6426 8188

    About Tessa Therapeutics

    Tessa Therapeutics is a clinical stage biopharmaceutical company with the scientific vision of revolutionizing the treatment of cancer by redirecting the body’s potent anti-viral immune response to recognize and kill cancer cells. Tessa’s virus-specific T cell (VST) platform has shown compelling results in the treatment of solid tumors, and the Company is building a portfolio of therapies addressing a wide range of tumors by combining the qualities of its T cell platform with complementary technologies. Tessa’s lead Phase III trial for nasopharyngeal carcinoma (NPC) is the world’s largest Phase III T cell immunotherapy trial for any cancer indication. The Company is also conducting a Phase I trial targeting cervical cancer and oropharyngeal cancer which is expected to move into Phase II in 2019. In addition, Tessa is developing a broad pipeline of pre-clinical programs targeting major cancers such as liver and lung cancer. The Company has built up robust operational and supply chain capabilities to successfully deliver T cell therapy treatments to a large patient pool across five countries. The combination of technologies from its academic, clinical, and commercial research partners have enabled Tessa to create a fully-integrated approach to the treatment of cancer with immunotherapy. For more information on Tessa, please visit www.tessatherapeutics.com.

  • Tessa Therapeutics featured on CNBC Capital Connection

    Date: 13 Aug 2018 

    Tessa’s CFO, Desmond Lim spoke on Tessa’s plans for the future and the promise of Virus-Specific T Cell (VST) cancer immunotherapy. Watch the interview here.

    ***

    Tessa Therapeutics Media Contacts
    Brunswick Group
    Will Carnwath, Ben Fry
    TessaTherapeutics@brunswickgroup.com
    +65 6426 8188

    About Tessa Therapeutics

    Tessa Therapeutics is a clinical stage biopharmaceutical company with the scientific vision of revolutionizing the treatment of cancer by redirecting the body’s potent anti-viral immune response to recognize and kill cancer cells. Tessa’s virus-specific T cell (VST) platform has shown compelling results in the treatment of solid tumors, and the Company is building a portfolio of therapies addressing a wide range of tumors by combining the qualities of its T cell platform with complementary technologies. Tessa’s lead Phase III trial for nasopharyngeal carcinoma (NPC) is the world’s largest Phase III T cell immunotherapy trial for any cancer indication. The Company is also conducting a Phase I trial targeting cervical cancer and oropharyngeal cancer which is expected to move into Phase II in 2019. In addition, Tessa is developing a broad pipeline of pre-clinical programs targeting major cancers such as liver and lung cancer. The Company has built up robust operational and supply chain capabilities to successfully deliver T cell therapy treatments to a large patient pool across five countries. The combination of technologies from its academic, clinical, and commercial research partners have enabled Tessa to create a fully-integrated approach to the treatment of cancer with immunotherapy. For more information on Tessa, please visit www.tessatherapeutics.com.

  • Baylor College of Medicine partnership extended to include development of novel combination therapies to treat liver and lung cancers.

    Baylor Medical College, Houston, Texas (Baylor) is a leading pioneer in the development of Virus-Specific T Cell technology for the treatment of cancers.  In October 2016, Tessa Therapeutics further cemented its research partnership with Baylor by signing a co-development agreement to develop novel combination therapeutics for liver cancer and lung cancer by combining CAR-T Cell and Virus-Specific T Cell technologies. Tessa Therapeutics has exclusive rights to license all IP generated under the Co-Development Program, which will initially focus on pre-clinical development of at least two therapeutic candidates for both liver, and lung cancer, followed by early stage clinical evaluation.

  • Acquisition of oncology antibody company EuChloe Bio provides Tessa Therapeutics with additional and complementary capabilities to extend its core technologies to treat a broad range of cancers

    EuChloe Bio (EuChloe) is a biotechnology company specializing in the discovery and engineering of humanized monoclonal antibodies. With this acquisition, Tessa Therapeutics now possesses a pipeline of novel antibodies that are able to enhance and widen the application of its cellular immunotherapies to treat a broader range of cancer indications.

  • Strategic alliance with National Cancer Centre Singapore to facilitate large scale clinical trials and commercialization of immunotherapy cancer treatments

    The National Cancer Centre Singapore (NCCS) was established in 1999 to further enhance the country’s position as a preeminent center for cancer research, education and treatment in Asia Pacific. In July 2014, NCCS and Tessa Therapeutics entered into a research collaboration in the field of cellular therapy.

    In June 2016, NCCS and Tessa Therapeutics expanded their research partnership with the formation of a broad strategic alliance. The alliance encompasses research, large-scale clinical trials and the development of world leading GMP manufacturing to facilitate the development, evaluation and commercialization of immune-oncology treatments for a wide range of cancers. NCCS has granted Tessa Therapeutics exclusive rights to license and commercialize all cancer immunotherapy products and technologies arising from NCCS’ immunotherapy research.  NCCS is also a strategic shareholder in Tessa Therapeutics.

  • Tessa Therapeutics’ head and neck cancer therapy granted Fast Track designation

    The US Food and Drug Administration (FDA) granted Fast Track designation to Tessa Therapeutics’ EBV-specific adoptive T Cell therapy for head and neck cancers in September 2015. The designation enables Tessa Therapeutics to have more frequent interactions with the agency, including a potential rolling review of Tessa Therapeutics’ application, and the ability to expedite the development of Tessa Therapeutics’ EBV-specific adoptive T Cell therapy.

  • FDA approves initiation of Phase I clinical trial for cervical cancer and oropharyngeal cancer

    Tessa Therapeutics’ research partner, Baylor College of Medicine (Baylor), received US Food and Drug Administration (FDA) approval in June 2015 to initiate Phase I clinical trials involving adoptive HPV-specific T Cell therapy to treat HPV-associated cervical cancer and oropharyngeal cancer. Approximately 700,000 new cases of cervical cancer and oropharyngeal cancer are diagnosed every year, with up to 70- 80% of these cases being positive for HPV.

  • FDA approves initiation of Phase III clinical trial for nasopharyngeal cancer

    Tessa Therapeutics received US Food and Drug Administration (FDA) approval in March 2015 to initiate a Phase III clinical trial involving adoptive EBV-specific T Cell therapy to treat nasopharyngeal cancer. This is the world’s first and largest Phase III T Cell therapy cancer trial. Tessa Therapeutics has an exclusive license to EBV-specific T Cell technology from the National Cancer Centre Singapore (NCCS).